Dinaciclib

DRUG13 trials

Sponsors

National Cancer Institute (NCI), Merck Sharp & Dohme LLC, Jo Chien, AbbVie

Conditions

Acral Lentiginous MelanomaAdvanced Malignant Solid NeoplasmAdvanced or Metastatic Breast CancerCancer - Acute Myeloid LeukemiaChronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia (CLL)Cutaneous Nodular MelanomaEstrogen Receptor Negative

Phase 1

Dinaciclib in Treating Patients With Stage III-IV Melanoma

TerminatedNCT01026324

National Cancer Institute (NCI)Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma

Start: 2009-09-30End: 2014-10-31Updated: 2017-04-04

Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors

Active, not recruitingNCT01434316

National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm

Start: 2011-11-11End: 2027-08-02Updated: 2026-08-03

Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

CompletedNCT01515176

National Cancer Institute (NCI)Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma +1

Start: 2012-01-31End: 2016-07-19Updated: 2018-03-15

Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

CompletedNCT01624441

National Cancer Institute (NCI)Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma +4

Start: 2012-08-21End: 2013-09-10Updated: 2018-03-30

A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)

CompletedNCT01650727

Merck Sharp & Dohme LLCChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Start: 2012-10-31End: 2013-10-31Updated: 2015-02-10

Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

CompletedNCT01676753

Jo ChienAdvanced or Metastatic Breast Cancer, Triple Negative Breast Cancer

Start: 2016-12-28End: 2022-02-28Updated: 2022-09-21

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

CompletedNCT01711528

National Cancer Institute (NCI)Recurrent Plasma Cell Myeloma

Start: 2012-12-19End: 2016-11-22Updated: 2018-05-11

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

CompletedNCT01783171

National Cancer Institute (NCI)Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7 +2

Start: 2013-01-15End: 2016-07-12Updated: 2017-08-22

Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)

TerminatedNCT02684617

Merck Sharp & Dohme LLCrrCLL, rrDLBCL, rrMM

Start: 2016-03-29End: 2020-04-06Updated: 2021-03-01

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

TerminatedNCT03484520

AbbVieCancer - Acute Myeloid Leukemia

Start: 2018-07-23End: 2022-12-01Updated: 2022-12-30

Phase 2

Dinaciclib in Treating Patients With Stage IV Melanoma

Active, not recruitingNCT00937937

National Cancer Institute (NCI)Acral Lentiginous Melanoma, Cutaneous Nodular Melanoma, Lentigo Maligna Melanoma +4

Start: 2009-07-01End: 2027-03-19Updated: 2026-09-14

Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma

CompletedNCT01096342

National Cancer Institute (NCI)Refractory Multiple Myeloma

Start: 2009-07-31End: 2012-12-31Updated: 2014-06-18

Phase 3

A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714)

CompletedNCT01580228

Merck Sharp & Dohme LLCChronic Lymphocytic Leukemia (CLL)

Start: 2012-08-31End: 2014-12-31Updated: 2017-02-23

Related Papers

Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma

Cancer2024-09-297 citations

Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study

Blood Advances2021-12-3135 citations

A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.

Journal of Clinical Oncology2020-05-2017 citations

ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE‐155 STUDY

Hematological Oncology2019-06-016 citations

PS1075 ANTITUMOR ACTIVITY OF PEMBROLIZUMAB PLUS DINACICLIB IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA: THE PHASE 1B KEYNOTE‐155 STUDY

HemaSphere2019-06-011 citations

A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC).

Journal of Clinical Oncology2019-05-205 citations

Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models

Molecular Cancer Therapeutics2015-04-3064 citations

Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma

Blood2014-11-14250 citations

A phase 1 study of dinaciclib (SCH 727965) in combination with epirubicinin patients with metastatic triple-negative breast cancer.

Journal of Clinical Oncology2014-09-103 citations